Review of: "Synthesis of 1, 2-Disubstituted Benzimidazoles at Ambient Temperature Catalyzed by 1-Methylimidazolium Tetraflouroborate ([Hmim] BF_4) and Investigating Their Anti-ovarian Cancer Properties Through Molecular Docking Studies and Calculations"

Raúl Díaz-Molina[1]

1 Autonomous University of Baja California

Potential competing interests: No potential competing interests to declare.

I believe this is an interesting work that could be improved in terms of its structure and wording. Based on my observations, I suggest the following:

The abstract should be structured based on an introductory part, objective, methodology, results, and conclusions (although the names of these sections are not mentioned in the abstract).

I suggest that in the introductory part, you include current information on the prevalence and incidence of ovarian cancer in the world and in the country of origin of the publication, as well as data on ovarian cancer mortality.

I recommend that the introduction include information on the current compounds used for the treatment of ovarian cancer, with a focus on their advantages and disadvantages. This will support the development of new organic drugs.

In Scheme 1, please indicate the reaction time.

Please note that Table 1 and Table 2 have practically the same title. This aspect should be improved.

It is necessary to indicate the meaning of the abbreviations used in the tables, figures, or schemes.

Please explain why the -R symbol is used in one of the products (and not in the reagents) in Table 1.

The authors utilize the designation CD-125; however, it is unclear if this is an accurate representation. It is recommended that the designation be revised to CA-125.

The authors utilize the CD-125 protein to assess the potential interaction of this protein with the synthesized molecules. However, they do not justify the use of this protein for docking. It would be more beneficial to focus on altered signaling pathways in ovarian cancer to evaluate the potential use as inhibitors of these pathways.